Abstract
Treatment is what really counts for our patients. The prerequisites for successful treatment and improvement of quality of life and functions may be summarised as the four CDs: correct diagnosis, correct drug, correct dosage and correct duration. The correct dosage and the correct duration, with re-evaluations of the patients to monitor the efficacy of the treatment, are of particular importance and are often neglected. This month’s Journal Club will focus on three related aspects of treatment: 1) Long-term effects of pallidal deep brain stimulation in tardive dystonia. 2) The risks and costs of multiple-generic substitution, an issue which is becoming increasingly relevant due to the multiplegenerics on the market. 3) A new treatment principle for vestibular schwannomas in neurofibromatosis type 2: use of the anti-vascular endothelial growth factor monoclonal antibody bevacizumab. Long-term effects of pallidal deep brain stimulation in tardive dystonia
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
